Rainbow Children’s Medicare Limited announced its financial results for the first quarter of FY27, reporting a significant 33% year-on-year increase in revenue from operations to ₹4,699.9 million. EBITDA also saw a substantial rise of 30% to ₹1,346.5 million, demonstrating strong operational performance and growth for the quarter ending June 30, 2026.
Rainbow Children’s Medicare Limited Reports Strong Q1 FY27 Performance
Rainbow Children’s Medicare Limited has announced robust financial results for the first quarter of the financial year 2026-27 (Q1 FY27), ending on June 30, 2026. The company demonstrated significant year-on-year growth across key financial metrics, underscoring a positive operational trajectory.
Financial Highlights: Q1 FY27
The company reported a substantial 33% increase in Revenue from operations, reaching ₹4,699.9 million for Q1 FY27, compared to ₹3,529.3 million in the same quarter of the previous year (Q1 FY26). Total income also grew by 29% to ₹4,827.0 million.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a healthy 30% rise, standing at ₹1,346.5 million for Q1 FY27, up from ₹1,036.2 million in Q1 FY26. The EBITDA margin improved to 28.6% from 23.1%.
Profit After Tax (PAT) for the quarter stood at ₹625.4 million, marking a 16% increase compared to ₹538.0 million in Q1 FY26. The PAT margin was 13.3%.
Consolidated Statement of Profit and Loss
The consolidated statement of profit and loss further details the company’s financial health. Total income for Q1 FY27 was ₹4,827.0 million, a 29% YoY growth. Total expenses also increased by 32% to ₹3,987.4 million. Profit before tax rose by 18% to ₹839.5 million.
Key expense line items showing significant year-on-year increases include Cost of materials consumed (36%), Employee benefits expense (30%), and Professional fees to doctors (35%).
Operational Performance Indicators
Operational Key Performance Indicators (KPIs) for Q1 FY27 highlight sustained growth. The number of operational beds increased by 26% to 2,375. In-patient Discharges saw a growth of 28% to 26,886, while Out-patient Consultations grew by 25% to 4,10,590. Deliveries also increased by 23% to 4,910.
Occupancy rates for Q1 FY27 were 41.2% for capacity beds and 45.3% for operational beds. ARPOB (Average Revenue Per Occupied Bed) stood at ₹67,256, while ALOS (Average Length of Stay) was 2.60 days.
Payor Profile
In Q1 FY27, the payor profile for Inpatient Income showed a split of 51.7% Cash and 48.3% Insurance, a slight shift from Q1 FY26 where it was 51.8% Cash and 48.3% Insurance.
Expansion Plans
The company’s expansion plans include adding 145 beds in FY26-27, with further expansions planned in subsequent years, targeting a total of 3,725 beds by FY28-29. Key growth areas include Telangana, Bengaluru, Tamil Nadu, National Capital Region, Andhra Pradesh, North East, Central India, and Maharashtra.
Shareholding Pattern
As of June 30, 2026, the Promoter & Promoter Group holds 49.8% of the shareholding. Mutual Funds & AIFs hold 19.9%, followed by FPIs & NRIs at 16.0%, and Others at 14.3%.
Source: BSE
